De-Novo B-Cell Prolymphocytic Leukemia.
Menakuru SR, Roepke J, Siddiqui S.
J Hematol. 2023 Apr;12(2):82-86. doi: 10.14740/jh1096. Epub 2023 Apr 30.
B-cell prolymphocytic leukemia after COVID-19 infection.
Falini B, Lazzi S.
Blood. 2023 Apr 6;141(14):1777. doi: 10.1182/blood.2023019816.
B-cell prolymphocytic leukemia has 3 subsets.
Kay NE, Hanson CA.
Blood. 2019 Nov 21;134(21):1777-1778. doi: 10.1182/blood.2019003046.
Lymphoproliferative Disorders.
Justiz Vaillant AA, Stang CM.
2023 Aug 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Understanding splenic B-cell lymphoma/leukaemia with prominent nucleoli: Diagnosis, underpinnings for disease classification and future directions.
Naresh KN.
Br J Haematol. 2024 Dec;205(6):2142-2152. doi: 10.1111/bjh.19754. Epub 2024 Sep 10.
An illustrative case of B-cell prolymphocytic leukemia.
Jain A, Khunger JM, Prasad P, Chaudhry S, Sharma M, Gupta DK, Saluja S.
Blood Res. 2020 Sep 30;55(3):181-184. doi: 10.5045/br.2020.2020079.
PEITC in End-Stage B-Cell Prolymphocytic Leukemia: Case Report of Possible Sensitization to Salvage R-CHOP.
Nachat A, Turoff-Ortmeyer S, Liu C, Mcculloch M.
Perm J. 2016 Spring;20(2):74-80. doi: 10.7812/TPP/15-153.
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes.
Charalampopoulou S, Chapiro E, Nadeu F, Zenz T, Beà S, Martínez-Farran A, Aymerich M, Rozman M, Roos-Weil D, Bernard O, Susin SA, Parker H, Walewska R, Oakes CC, Strefford JC, Campo E, Matutes E, Duran-Ferrer M, Nguyen-Khac F, Martín-Subero JI.
Blood Adv. 2024 Dec 24;8(24):6297-6307. doi: 10.1182/bloodadvances.2024013327.
Prolymphocytic leukemia.
Absi A, Hsi E, Kalaycio M.
Curr Treat Options Oncol. 2005 May;6(3):197-208. doi: 10.1007/s11864-005-0003-4.
B and T cell prolymphocytic leukaemia.
Cross M, Dearden C.
Best Pract Res Clin Haematol. 2019 Sep;32(3):217-228. doi: 10.1016/j.beha.2019.06.001. Epub 2019 Jun 6.
